34 completed, 14 recruiting, 6 terminated, 4 unknown. 30 Phase 2, 22 Phase 3, 18 Phase 1, 2 Not applicable, 2 Phase 4.
Follow sarilumab: new trials by email Literature Review of sarilumab trials Research Report on sarilumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency) - Metastatic Castration-Resistant Prostate Cancer, mCRPC | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 192 | 2027-06-28 | 2026-09-30 |
| Study of Sarilumab With Immune Checkpoint Inhibitor Rechallenge in Patients With Clinically Significant Immune Related Adverse Events Sarilumab, ICI Therapy - Any Advanced Solid Tumors | Phase 2 | Not yet recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 41 | 2026-10-01 | 2026-09-23 |
| IL6-receptor Inhibitor Iwith Belumosudil for the Treatment of Belumosudil-refractory cGVHD Belumosudil, Sarilumab - cGVHD | Phase 1 | Not yet recruiting | Stanford University | 10 | 2026-09-01 | 2026-08-12 |
| Phase 1b/2 Study of IV Sarilumab in Adult With RA Sarilumab, SAR153191 SC, Sarilumab, SAR153191 IV - Rheumatoid Arthritis | Phase 1 / Phase 2 | Recruiting | Sanofi | 140 | 2026-07-02 | 2026-10-13 |
| Sarilumab Efficacy and Safety in Adults With Early Polymyalgia Rheumatica Sarilumab, Placebo - Polymyalgia Rheumatica | Phase 3 | Recruiting | Sanofi | 300 | 2026-05-12 | 2026-10-21 |
| A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Ubamatamab, Marlotamig, Sarilumab - Non Small Cell Lung Cancer, Advanced Non Small Cell Lung Cancer | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 300 | 2026-03-18 | 2026-10-22 |
| Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer Ubamatamab, Bevacizumab, Cemiplimab - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 297 | 2025-05-28 | 2026-09-14 |
| A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept - Rheumatoid Arthritis | Completed | Pfizer | 21340 | 2024-05-15 | 2025-07-31 | |
| A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer. Cemiplimab, Kevzara (Sarilumab) - Lung Cancer | Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 56 | 2023-08-18 | 2026-10-06 |
| Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma Sarilumab, Ipilimumab Injection, Nivolumab/Relatlimab - Melanoma, Unresectable Melanoma | Phase 2 | Recruiting | NYU Langone Health | 105 | 2023-02-02 | 2026-01-05 |
| Stand UP to Rheumatoid Arthritis (SUPRA) TNFi, Anti-IL6, JAKi - Rheumatoid Arthritis | Not applicable | Recruiting | Marie Hudson, MD | 75 | 2023-02-01 | 2026-02-03 |
| Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation Squaric Acid Dibutyl Ester, Known patch test allergens, Dupilumab - Skin Inflammation, Allergic Contact Dermatitis | Phase 2 / Phase 3 | Active not recruiting | Wei-Che Ko | 45 | 2022-11-15 | 2026-06-09 |
| Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis Discontinuation of biological/targeted synthetic disease modifying anti-rheumatic drug (b/tsDMARD) - Rheumatoid Arthritis | Not applicable | Unknown | Medical University of Vienna | 85 | 2022-03-01 | 2021-11-15 |
| Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis Tocilizumab, Sarilumab - Arthritis, Rheumatoid, Interaction | Phase 1 / Phase 2 | Terminated | University of Southern Denmark | 3 | 2021-05-25 | 2023-01-25 |
| Study on the Use of Sarilumab in Patients With COVID-19 Infection Sarilumab Prefilled Syringe - COVID19 | Early Phase 1 | Withdrawn | ASST Fatebenefratelli Sacco | 2021-01-01 | 2023-02-03 | |
| A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab REGN5668, Cemiplimab, Ubamatamab - Ovarian Cancer, Fallopian Tube Cancer | Phase 1 / Phase 2 | Recruiting | Regeneron Pharmaceuticals | 612 | 2020-12-08 | 2026-09-24 |
| A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) Capecitabine, Sarilumab 150mg or 200 mg plus Capecitabine, Sarilumab 150mg plus Capecitabine - Breast, Metastatic | Phase 1 / Phase 2 | Recruiting | University of Southern California | 65 | 2020-09-26 | 2026-03-10 |
| Methodologies for Observational Studies Comparing Inpatient COVID-19 Treatments Initiation of IL6Ri (tocilizumab or sarilumab) versus JAKi (baricitinib or tofacitinib) added to systemic corticosteroids of interest (CSI) - COVID-19 | Completed | Aetion, Inc. | 1442 | 2020-06-16 | 2024-09-19 | |
| Subcutaneous Sarilumab vs Placebo in Hospitalized Patients With Respiratory Distress Caused by COVID 19 Sarilumab 200 MG/1.14 ML Subcutaneous Solution, Placebo - COVID, COVID-19 | Phase 2 | Withdrawn | BayCare Health System | 2020-05-07 | 2025-09-29 | |
| Effect of Sarilumab on Atherosclerotic Disease Assessed by PET/CET in Patients With RA (SARIPET) Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA] - Rheumatoid Arthritis, Atherosclerosis | Phase 4 | Unknown | Instituto de Investigación Marqués de Valdecilla | 20 | 2020-04-30 | 2020-04-27 |
Showing 20 of 67. Sign in to see all of them.
Arthritis, Rheumatoid (29) · COVID-19 (8) · Coronavirus Infections (7) · Fallopian Tube Neoplasms (3) · Ovarian Neoplasms (3) · Arthritis, Juvenile (2) · Endometrial Neoplasms (2) · Lung Neoplasms (2) · Neoplasms (2) · Pneumonia (2) · Polymyalgia Rheumatica (2) · Spondylitis, Ankylosing (2) · Adrenal Insufficiency (1) · Arrhythmias, Cardiac (1) · Atherosclerosis (1)
Sanofi (28) · Regeneron Pharmaceuticals (10) · Assistance Publique - Hôpitaux de Paris (2) · Stanford University (2) · ASST Fatebenefratelli Sacco (1) · Aetion, Inc. (1) · BayCare Health System (1) · Clinica Universidad de Navarra, Universidad de Navarra (1) · Duke University (1) · Gaylis, Norman B., M.D. (1) · GlaxoSmithKline (1) · Instituto de Investigación Marqués de Valdecilla (1) · M.D. Anderson Cancer Center (1) · Maimónides Biomedical Research Institute of Córdoba (1) · Maria del Rosario Garcia de Vicuña Pinedo (1)
United States (46) · Spain (23) · Canada (17) · France (16) · Czechia (15) · Italy (15) · Germany (14) · Hungary (14) · Russia (14) · Belgium (12) · Poland (12) · Argentina (11) · Netherlands (11) · United Kingdom (11) · Australia (10)
Allen Radin, MD (2) · Aliyah Pabani, MD (1) · Allen Radin, M.D. (1) · Anastasia Martynova, MD (1) · Ann-Cathrine Dunvald, MD (1) · Chi Hornik (1) · Colin McArthur, Dr (1) · Danielle Mauck, BA (1) · Derek Angus, Prof (1) · Hirsh D Komarow, M.D. (1) · James R O'Dell, MD (1)
PMID 34519964, PMID 36413080, PMID 32453485, PMID 32522251, PMID 32907617, PMID 36008838, PMID 30590833, PMID 30877216, PMID 31452928, PMID 32343882, PMID 33871596, PMID 36727470, PMID 21796368, PMID 22198468, PMID 22623692, PMID 22649152, PMID 24297381, PMID 24550171, PMID 25733246, PMID 27406346, PMID 27406347, PMID 27716324, PMID 27722854, PMID 27856432, PMID 27860410, PMID 28326189, PMID 28851423, PMID 29209946, PMID 29556418, PMID 30894208, PMID 31004324, PMID 31090044, PMID 31673415, PMID 32031889, PMID 32053137, PMID 32264972, PMID 32267771, PMID 32450725, PMID 32701140, PMID 32876697, PMID 32907638, PMID 33081825, PMID 33164349, PMID 33191263, PMID 33394942, PMID 33509275, PMID 33631065, PMID 33676590, PMID 34251506, PMID 34351721
2017 (3), 2009 (2), 2015 (2), 2014 (1), 2019 (1), 2023 (1), R01CA238387 (1)